Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).

Lactate dehydrogenase, creatinine kinase predict survival, poor prognosis in lung cancer

12 Sep 2017

Similar to their role in other cancers, plasma concentrations of lactate dehydrogenase (LDH) and creatinine kinase (CK) are independent predictors of survival and poor prognosis in lung cancer patients, particularly those with adenocarcinoma, a new study reveals.

The study included 1,142 lung cancer patients (69.2 percent male), of which 678 were positive for CK and 464 were negative, with respect to cut-off values. In comparison, 410 were LDH positive and 732 were negative.

In lung adenocarcinoma patients (n=608), bone metastasis was significantly more common in CK-negative than in CK-positive patients (27.6 vs 19.4 percent; p<0.05), while a stage four disease was significantly more common in in LDH-positive than in LDH-negative patients (72.5 vs 57.2 percent; p<0.05).

Elevated LDH levels were also significantly associated with metastasis to the bone (p<0.001), liver (p<0.001) and adrenal gland (p<0.001).

On the other hand, squamous cell carcinoma patients (n=307) that were positive for CK showed lower bone metastasis compared to those who were negative (6.8 vs 16.8 percent). Metastasis to other regions was not related to CK levels. LDH level was not significantly associated with any of the clinical characteristics.

In all lung cancer patients, lower plasma CK was associated with significantly poorer overall survival status (p<0.001), while higher LDH levels were linked to significantly poorer outcomes (p<0.001).

In those with adenocarcinoma, lower CH and higher LDH were associated with poor survival status (p<0.001 for both), while in squamous cell carcinoma patients, only CK concentration was tied to survival (p<0.05).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).